Pharmaceutical

AbbVie wins UK NICE endorsement for subcutaneous Tepkinly in DLBCL

AbbVie’s Tepkinly has been recommended for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Feb 2, 2024 - 18:00
AbbVie wins UK NICE endorsement for subcutaneous Tepkinly in DLBCL
AbbVie’s Tepkinly has been recommended for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Read the original article

Tags:

Previous Article

IGC Pharma heads towards a Phase I study for Alzheimer’s disease

Next Article

As England’s virus hospitalisations surge flu vaccines evolve

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Colorado could cap payments for Amgen’s Enbrel

Colorado could cap payments for Amgen’s Enbrel

Feb 23, 2024

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s ...

Apr 27, 2023

STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds

STAT+: More drug and device patents were invalidated fo...

Nov 15, 2023